Genzyme Corp. has begun treating patients in a Phase II trial examining the safety and effectiveness of Clolar in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. This is Genzyme’s second pivotal clinical study of Clolar in adult patients with AML to commence this year, and it is expected to provide substantial support for expanding the current product label. “We are very pleased to begin ...